Normal 0 false false false MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman"; mso-ansi-language:#0400; mso-fareast-language:#0400; mso-bidi-language:#0400;}

Normal 0 false false false MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman"; mso-ansi-language:#0400; mso-fareast-language:#0400; mso-bidi-language:#0400;}

GlobalData’s analysis suggests that the global Urinary Tract Infection (UTI) market was worth $371.5m in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.1% for the next seven years to reach $456.2m by 2016. The market is expected to be driven by the increase in usage of newly launched antibiotics for the treatment of complicated urinary tract infections and the increase in the prevalence and diagnosis of urinary tract infections. The patent expiry of one of the most efficacious drugs, Levaquin, in 2010 is expected to drive market revenues down. The FDA has recently approved Sandoz’s generic version of Levofloxacin in 2010. The impact of patent expiry is expected to be softened by the increase in revenue contribution of recently launched carbapenems for the treatment of complicated urinary tract infections.

 

For further details, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/Report.aspx?ID=Urinary-Tract-InfectionsUTI-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

 

GlobalData analyzed the current competitive landscape for UTI drugs and found the competition to be strong. There are more than seven classes of antibiotics used to treat urinary tract infections. Almost all marketed products have strong efficacy profiles and good safety profiles. In addition, ciprofloxacin, the most prescribed fluoroquinolone, is available as a low cost generic and therefore there is intense competition in the market. Fluoroquinolones have emerged as the most prescribed antibiotics for UTIs due to their excellent efficacy and safety profiles. They have replaced trimethoprim/sulfamethoxazole as the first-choice treatment option, despite the latter being the recommended therapeutic option in the guidelines of major international institutions. The patent expiry of Levaquin is expected to increase the competition within the fluoroquinolone class of antibiotics. Sandoz is expected to capture most of the market available for levofloxacin generics due to its first mover advantage.

 

GlobalData has found that the global UTI market is not very attractive for investors looking to generate significant revenues from the market. The market has highly efficacious products with good safety profiles and therefore the currently marketed products meet the needs of most of the patient population. In addition, highly prescribed antibiotics such as ciprofloxacin, trimethoprim/sulfamethoxazole and nitrofurantoin are already available as low cost generics. The unmet needs in the market are very small for investors to capitalize on. These unmet needs are due to the increasing bacterial resistance to the current set of antibiotics. Therefore, specialty pharmaceutical companies which are focused on developing antibiotics for resistant strains are the most active in the clinical development arena. Molecules that can treat strains that are resistant to the most prescribed therapies or those that can treat multiple-resistant strains can capitalize on the unmet needs.

 

For further details, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/Report.aspx?ID=Urinary-Tract-InfectionsUTI-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

 

GlobalData analyzed the UTI pipeline and found it to be weak. There are very few pipeline molecules in the later stages of development for the treatment of UTI. The few promising molecules that are in development are being targeted at strains that are resistant to older antibiotics and at gram-negative strains, which have very few therapeutic options. In addition, most of the molecules in development are either cell envelope inhibitors or nucleic acid inhibitors, both of which are already prevalent mechanisms of actions in the current market.

 

GlobalData has released its research, “Urinary Tract Infections - Drug Pipeline Analysis and Market Forecasts to 2016” which provides key data, information and analysis on the urinary tract infections market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts forward seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with urinary tract infections, competitive assessment, product profiles of major marketed products and promising drugs in the pipeline, implications for future market competition, and the key players of the urinary tract infections market.

 

For further details, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/Report.aspx?ID=Urinary-Tract-InfectionsUTI-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

 

Or Visit our report store: http://www.globaldata.com/reportstore

 

Share It!

Featured

release-news.com Webutation